Focus on the launch trajectory and payer coverage for FAYUVI in the coming quarters. The key catalysts are initial prescription uptake, patient identification rates, and any competitive pipeline updates from other MPS IIIA programs.
Price Chart
Executive Summary
Ultragenyx announced FDA approval of FAYUVI (UX-101) as the first-ever treatment for Sanfilippo syndrome Type A (MPS IIIA), a rare and devastating neurodegenerative disease. This is a transformative event for the company, as FAYUVI is its first approved therapy for a large, unmet-need pediatric population, unlocking a significant commercial opportunity.
Key Facts
- FAYUVI (UX-101) is the first FDA-approved treatment for Sanfilippo syndrome Type A (MPS IIIA).
- The approval addresses a previously untreatable, progressive neurodegenerative disease with no approved therapies.
- This is a first-in-class approval for Ultragenyx, marking its entry into the commercial stage for this indication.
Financial Impact
Transformative for Ultragenyx; FAYUVI is a first-to-market therapy for a severe, high-unmet-need rare disease, likely commanding premium pricing and capturing a large share of the diagnosed patient population.
Risk Factors
- Commercial launch execution and patient identification/access may be slower than expected.
- Pricing and reimbursement negotiations could limit peak revenue potential.
- Potential future competition from other MPS IIIA therapies in development.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3364357 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | SC 13G | $15.92 | awaiting T+5 | — | $16.75 (+5.21%) |
Oct 19, 2026 8d ago | 8-K | $15.07 $16.08 | ▲ +6.70% | ▲ +6.85% | $16.75 (+11.15%) |
Oct 14, 2026 13d ago | 8-K | $14.90 $15.92 | ▲ +6.85% | ▲ +6.39% | $16.75 (+12.42%) |
Oct 7, 2026 20d ago | 8-K | $14.89 $14.90 | ▲ +0.07% | ▲ +1.05% | $16.75 (+12.49%) |
Sep 17, 2026 5w ago | Press Release | $14.50 $14.77 | ▲ +1.86% | ▲ +1.01% | $16.75 (+15.52%) |
Sep 2, 2026 7w ago | 8-K | $14.85 $14.30 | ▲ +3.70% | ▲ +2.56% | $16.75 (−12.79%) |
Sep 1, 2026 8w ago | Press Release | $26.53 $14.40 | ▼ −45.72% | ▼ −44.76% | $16.75 (−36.86%) |
Aug 11, 2026 11w ago | 8-K | $26.80 $25.49 | ▼ −4.89% | ▼ −4.48% | $16.75 (−37.50%) |
Aug 4, 2026 12w ago | 8-K | $24.93 $26.86 | ▲ +7.74% | ▲ +7.39% | $16.75 (−32.81%) |
Aug 4, 2026 12w ago | Insider Cluster | $25.81 $26.96 | ▲ +4.46% | ▲ +4.56% | $16.75 (−35.10%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers